Hyderabad based NATCO Pharma Limited had recorded an increase of 26% in its earnings for the 2nd quarter of fiscal 2009 (Rs. 114 Crores) over the same quarter last year (Rs. 90 Crores). The net profit for the quarter, after tax, at Rs. 1187 lakhs, also recorded an increase of 12% over Rs. 1057 lakhs for the same quarter last year.

During the quarter, the Company had launched Albupax, (consisting of Paclitaxel in an Albumin bound nano-particle form), the first generic version of the international brand – Abraxane.


The Company has also received approval from the Drug Controller General of India for commencement of Phase I clinical trials for its new chemical entity which has multiple oncology indications. The clinical trials are expected to commence in November, 2008.